Semnur Pharmaceuticals Secures $100 Million Strategic Investment from iHolding Group to Advance Non-Opioid Pain Therapy SEMDEXA
Key Insights
Semnur Pharmaceuticals signed a binding term sheet with iHolding Group LLP (search) for a proposed $100 million strategic investment at $10.00 per share.
The funding will support the ongoing Phase 3 clinical program for SEMDEXA (SP-102), a novel non-opioid epidural gel for chronic radicular pain (search) and sciatica (search).
SEMDEXA holds FDA Fast Track designation and represents the first non-opioid gel formulation administered epidurally for moderate to severe chronic radicular pain (search).
Semnur Pharmaceuticals, Inc. (search), a clinical late-stage specialty pharmaceutical company and majority-owned subsidiary of Scilex Holding Company (search) (Nasdaq: SCLX), announced on July 7, 2026 the signing of a binding term sheet with iHolding Group LLP (search), a private investment group headquartered in Almaty, Republic of Kazakhstan. The term sheet contemplates iHolding purchasing $100,000,000 of newly issued shares of Semnur common stock at a price of $10.00 per share, representing approximately 10,000,000 shares.
The proposed investment is intended to support the continued advancement of Semnur's pipeline, including the ongoing Phase 3 clinical program for SEMDEXA (SP-102), as well as product development and commercialization activities, acquisitions and strategic partnerships, working capital and operational growth, intellectual property expansion, and other general corporate purposes.
SEMDEXA: A First-in-Class Non-Opioid Approach
SEMDEXA (SP-102) is a novel, viscous gel formulation of dexamethasone sodium phosphate, a widely used corticosteroid, designed for epidural injection to treat lumbosacral radicular pain (search), or sciatica (search). The product candidate is distinguished as the first non-opioid gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain (search). Scilex has completed a Phase 3 study for SEMDEXA, and the FDA granted the program Fast Track designation in 2017, underscoring the significant unmet medical need in this patient population.
Semnur, headquartered in Palo Alto, California, is focused exclusively on the development and commercialization of novel non-opioid pain therapies, positioning SEMDEXA as its lead asset in the growing push for alternatives to opioid-based analgesics.
Strategic Rationale and iHolding's Vision
In a joint statement, Alain Khoueiry, Chairman, and Byron Byrd, Chief Executive Officer of iHolding Group LLP (search), characterized the proposed investment as having "the potential to become a landmark transaction, demonstrating the growing capacity and international outlook of Kazakhstan-linked investment capital in supporting world-class biopharmaceutical innovation."
The leadership further emphasized that SEMDEXA, "with its FDA Fast Track designation and advanced Phase 3 clinical development programme, represents an opportunity to participate in a therapy that addresses a significant unmet medical need while supporting innovation at the highest level of the global life sciences industry."
iHolding articulated that the initiative aligns with its long-term strategy of helping establish Kazakhstan as a leading regional hub for pharmaceutical manufacturing, research and development, regulatory excellence, and international distribution. "Every strategic partnership of this quality strengthens the expertise, supply chain relationships, regulatory knowledge, and global industry connections necessary to build a sustainable life sciences ecosystem capable of serving Central Asia and international markets alike," the statement read.
Conditions and Next Steps
The proposed investment remains subject to completion of customary due diligence, the parties' negotiation and execution of definitive agreements, board approvals, and other customary closing conditions, including any required regulatory approvals. The transaction has not yet closed, and there can be no assurance that it will be completed on the terms described or at all.
Scilex Holding Company (search) and the Broader Pipeline
Scilex Holding Company (search), Semnur's majority owner, is an innovative revenue-generating company focused on non-opioid pain management. Scilex's commercial portfolio includes ZTlido (lidocaine topical system) 1.8% for postherpetic neuralgia, ELYXYB for acute migraine, and Gloperba for gout flare prophylaxis. Beyond SEMDEXA, Scilex's pipeline includes SP-103, a next-generation triple-strength lidocaine topical system with Fast Track designation for low back pain that has completed a Phase 2 trial, and SP-104, a low-dose naltrexone hydrochloride delayed-release capsule in development for fibromyalgia.
In a separate corporate development, Scilex announced on May 22, 2026 that its board of directors approved a dividend of Semnur common stock to Scilex stockholders and certain other eligible equityholders. Scilex, which holds approximately 186 million shares of Semnur common stock, plans to distribute approximately 10.7 million shares, with participating holders entitled to receive one share of Semnur common stock for each share of Scilex common stock held as of the June 1, 2026 record date.